Credit Suisse downgraded SelectQuote from Outperform to Neutral and set a new price target of $4.00 from $14.00 previously
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/30/2024 | $4.50 | Buy | Craig Hallum |
| 2/29/2024 | $5.00 | Outperform | Noble Capital Markets |
| 4/1/2022 | $4.00 | Neutral | Credit Suisse |
| 2/8/2022 | $9.00 → $5.00 | Equal Weight | Barclays |
| 2/8/2022 | $13.00 → $3.00 | Sector Perform | RBC Capital |
| 2/8/2022 | $20.00 → $4.00 | Overweight → Neutral | Piper Sandler |
| 2/8/2022 | $14.00 → $4.00 | Outperform → Neutral | Credit Suisse |
| 1/18/2022 | $21.00 → $9.00 | Overweight → Equal Weight | Barclays |
8-K - SelectQuote, Inc. (0001794783) (Filer)
10-Q - SelectQuote, Inc. (0001794783) (Filer)
8-K - SelectQuote, Inc. (0001794783) (Filer)
Second Quarter of Fiscal Year 2025 – Consolidated Earnings Highlights Revenue of $481.1 million Net income of $53.2 million Adjusted EBITDA* of $87.5 million Fiscal Year 2025 Guidance Ranges: Revenue expected in a range of $1.500 billion to $1.575 billion Net income (loss) expected in a range of $(24) million to $11 million Adjusted EBITDA* expected in a range of $115 million to $140 million Second Quarter Fiscal Year 2025 – Segment Highlights Senior Revenue of $255.6 million Adjusted EBITDA* of $100.5 million Approved Medicare Advantage policies of 247,849 Healthcare Services Revenue of $183.4 million Adjusted EBITDA* of $2.2 million 96,695 Se
SelectQuote, Inc. (NYSE:SLQT), a leading distributor of Medicare insurance policies and owner of a rapidly growing Healthcare Services platform, today announced it will release its second quarter 2025 financial results after market close on Monday, February 10, 2025. Chief Executive Officer, Tim Danker, and Chief Financial Officer, Ryan Clement, will host a conference call on the day of the release (February 10, 2025) at 5:00 pm ET to discuss the results. To register for this conference call, please use this link: https://registrations.events/direct/Q4I731198247. After registering, a confirmation will be sent via email, including dial in details and unique conference call codes for entr
First Quarter of Fiscal Year 2025 – Consolidated Earnings Highlights Revenue of $292.3 million Net loss of $44.5 million Adjusted EBITDA* of $(1.7) million Fiscal Year 2025 Guidance Ranges: Revenue expected in a range of $1.425 billion to $1.525 billion Net income (loss) expected in a range of $(59) million to $3 million Adjusted EBITDA* expected in a range of $100 million to $130 million First Quarter Fiscal Year 2025 – Segment Highlights Senior Revenue of $92.9 million Adjusted EBITDA* of $7.7 million Approved Medicare Advantage policies of 91,680 Healthcare Services Revenue of $155.7 million Adjusted EBITDA* of $4.9 million 86,521 SelectRx members Life
4 - SelectQuote, Inc. (0001794783) (Issuer)
4 - SelectQuote, Inc. (0001794783) (Issuer)
4 - SelectQuote, Inc. (0001794783) (Issuer)
Clement has served as Interim CFO since May 2022 SelectQuote, Inc. (NYSE:SLQT) today announced that the Board of Directors appointed Ryan Clement, SVP of Financial Planning & Analysis, to serve as the company's Chief Financial Officer. Clement was named interim CFO in May 2022. CEO Tim Danker commented, "Over the last year, Ryan has excelled as our Interim CFO and has demonstrated both the financial acumen and leadership qualities we are looking for in the company's next permanent CFO. Ryan has played a critical role in our strategic redesign that has vastly improved SelectQuote's operating results and financial stability and positions the company to execute on our objectives in the futur
4 - SelectQuote, Inc. (0001794783) (Issuer)
4 - SelectQuote, Inc. (0001794783) (Issuer)
4 - SelectQuote, Inc. (0001794783) (Issuer)
SelectQuote, Inc. (NYSE:SLQT) (the "Company"), a leading distributor of Medicare insurance policies and owner of a rapidly-growing healthcare services platform, today announced that the Company closed and received the proceeds from the $350 million strategic investment on February 28, 2025. The Company originally announced a binding agreement on the transaction with funds managed by Bain Capital, Morgan Stanley Private Credit, and Newlight Partners on February 10th. The Company used $260 million of proceeds to pay down its outstanding term loan. The Company now has more than $100 million of available liquidity as it continues to focus on its industry-leading insurance distribution busines
SelectQuote, Inc. (NYSE:SLQT) (the "Company"), a leading distributor of Medicare insurance policies and owner of a rapidly-growing healthcare services platform, today announced that the Company signed a $350 million strategic investment from funds managed by Bain Capital, Morgan Stanley Private Credit, and Newlight Partners. The transaction positions the Company to continue growing its healthcare services business, deepening its relationship with carrier partners and providing choice and value for consumers. This investment will allow the Company to recapitalize its balance sheet, to lower its annual cash debt service, and to provide liquidity and increase operating flexibility to fund gr
Second Quarter of Fiscal Year 2025 – Consolidated Earnings Highlights Revenue of $481.1 million Net income of $53.2 million Adjusted EBITDA* of $87.5 million Fiscal Year 2025 Guidance Ranges: Revenue expected in a range of $1.500 billion to $1.575 billion Net income (loss) expected in a range of $(24) million to $11 million Adjusted EBITDA* expected in a range of $115 million to $140 million Second Quarter Fiscal Year 2025 – Segment Highlights Senior Revenue of $255.6 million Adjusted EBITDA* of $100.5 million Approved Medicare Advantage policies of 247,849 Healthcare Services Revenue of $183.4 million Adjusted EBITDA* of $2.2 million 96,695 Se
SC 13G/A - SelectQuote, Inc. (0001794783) (Subject)
SC 13G/A - SelectQuote, Inc. (0001794783) (Subject)
SC 13G/A - SelectQuote, Inc. (0001794783) (Subject)
Craig Hallum initiated coverage of SelectQuote with a rating of Buy and set a new price target of $4.50
Noble Capital Markets initiated coverage of SelectQuote with a rating of Outperform and set a new price target of $5.00
Credit Suisse resumed coverage of SelectQuote with a rating of Neutral and set a new price target of $4.00